Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Transparency Initiative Sees No Clear Path To Releasing Documents, Woodcock Indicates

This article was originally published in The Pink Sheet Daily

Executive Summary

Requirements to redact proprietary information from documents, make them accessible to the disabled, and other challenges would greatly tax FDA staff, FDA's Janet Woodcock says.

You may also be interested in...



FDA Transparency Initiative: Disclosure Rules Could Expand, Then Be Harmonized

Following the release of FDA's Transparency Task Force report, the agency may want to add an agenda item to its harmonization discussions with EMA

FDA Transparency Initiative: Disclosure Rules Could Expand, Then Be Harmonized

Following the release of FDA's Transparency Task Force report, the agency may want to add an agenda item to its harmonization discussions with EMA

Can FDA Do The "Right Thing" On Transparency? Ask A Lawyer

Proposals from agency task force include releasing when applications are submitted and withdrawn along with FDA reasons for refuse-to-file and complete response letters.

Related Content

Topics

UsernamePublicRestriction

Register

PS070542

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel